
[Federal Register Volume 76, Number 245 (Wednesday, December 21, 2011)]
[Notices]
[Page 79195]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2011-32567]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2011-N-0656]


Animal Drug User Fee Act; Reopening of the Comment Period

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice; reopening of the comment period.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA or Agency) is extending 
to January 15, 2013, the comment period for the notice of public 
meeting; request for public comments that published in the Federal 
Register of September 20, 2011 (76 FR 58279). In that notice, FDA 
requested comments on the Animal Drug User Fee Act (ADUFA) program to 
date and solicited suggestions regarding the features FDA should 
propose for the next ADUFA program. The Agency is taking this action to 
ensure that interested persons have the option of submitting comments 
throughout the reauthorization of ADUFA.

DATES: Submit either electronic or written comments by January 15, 
2013.

ADDRESSES: Submit electronic comments to: http://www.regulations.gov. 
Submit written comments to the Division of Dockets Management (HFA-
305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, 
Rockville, MD 20852. Identify comments with the docket number found in 
brackets in the heading of this document.

FOR FURTHER INFORMATION CONTACT: Donal Parks, Center for Veterinary 
Medicine (HFV-010), Food and Drug Administration, 7519 Standish Pl., 
Rockville, MD 20855, (240) 276-8688, ADUFAReauthorization@fda.hhs.gov.

SUPPLEMENTARY INFORMATION:

I. Background

    In the Federal Register of September 20, 2011, FDA published a 
notice of public meeting; request for comments to solicit input from 
the public on what FDA should consider including in the reauthorization 
of ADUFA. FDA is interested in responses from the public on the 
following two general questions and welcomes other pertinent 
information that stakeholders would like to share:
    1. What is your assessment of the overall performance of the ADUFA 
program thus far?
    2. What aspects of ADUFA should be retained, changed, or 
discontinued to further strengthen and improve the program?
    Additional background materials, including the transcript of the 
public meeting, are available on the FDA's Web site.
    The Agency is reopening the comment period to allow members of the 
general public or of stakeholder groups the opportunity to provide 
comments throughout the process of reauthorizing ADUFA.

II. How to Submit Comments

    Interested persons may submit to the Division of Dockets Management 
(see ADDRESSES) either electronic or written comments on this document. 
It is only necessary to send one set of comments. It is no longer 
necessary to send two copies of mailed comments. Identify comments with 
the docket number found in brackets in the heading of this document. 
Received comments may be seen in the Division of Dockets Management 
between 9 a.m. and 4 p.m., Monday through Friday.

    Dated: December 15, 2011.
Leslie Kux,
Acting Assistant Commissioner for Policy.
[FR Doc. 2011-32567 Filed 12-20-11; 8:45 am]
BILLING CODE 4160-01-P


